Covid 19 Research using Clinical Trials (Home Page)
Report for D012008: Recurrence NIH
(Synonyms: Recurren, Recurrence)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2523 | SMS message support Wiki | 1.00 |
| drug2581 | Self-help booklet Wiki | 1.00 |
| drug645 | Chat-based instant messaging support Wiki | 1.00 |
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Chat-based Instant Messaging Support for Preventing Smoking Relapse in the Context of COVID-19 Outbreak: a Pilot Randomised Clinical Trial
This pilot trial aims to evaluate the effectiveness of chat-based instant messaging support in preventing smoking relapse in recent tobacco abstainers.
NCT04409496 Smoking Cessation Behavioral: Chat-based instant messaging support Behavioral: SMS message support Behavioral: Self-help booklet MeSH:Recurrence
Primary Outcomes
Description: Defined by an exhaled carbon monoxide level of 3 parts per million or below
Measure: Biochemically-validated tobacco abstinence Time: Assessed at 6 months after randomisationSecondary Outcomes
Description: Not more than five lapses permitted for 6 months after baseline
Measure: Self-reported 6-month prolonged tobacco abstinence Time: Assessed at 6 months after randomisationDescription: Being completely smoke-free in the past 7 days
Measure: Self-reported 7-day point-prevalence tobacco abstinence Time: Assessed at 3 months after randomisationDescription: Being completely smoke-free in the past 7 days
Measure: Self-reported 7-day point-prevalence tobacco abstinence Time: Assessed at 6 months after randomisationDescription: Defined as use of tobacco products for 7 consecutive days or longer
Measure: Self-reported relapse rate Time: Assessed at 3 months after randomisationDescription: Defined as use of tobacco products for 7 consecutive days or longer
Measure: Self-reported relapse rate Time: Assessed at 6 months after randomisationOther Outcomes
Description: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.
Measure: Change in self-efficacy to quit smoking Time: Assessed at 3 months after randomisationDescription: Assessed by the Chinese version of the Smoking Self-efficacy Questionnaire (SEQ-12), which contains 12 Likert items ranging from 1 (not certain at all) to 5 (very certain) with higher scores indicating greater perceived confidence in resisting smoking.
Measure: Change in self-efficacy to quit smoking Time: Assessed at 6 months after randomisationDescription: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.
Measure: Nicotine withdrawal Time: Assessed at 3 months after randomisationDescription: Assessed by the Chinese verion of the Minnesota Nicotine Withdrawal Scale (MNWS), which contains 9 Likert items ranging from 0 (not at all) to 4 (very severe) with higher scores indicating greater nicotine withdrawal.
Measure: Nicotine withdrawal Time: Assessed at 6 months after randomisation